INTRANASAL 0.15% AND 0.24% TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER
The present invention relates to lower dosage strength pernasal testosterone gel formulations for intranasal administration and treatment methods for using the lower dosage strength pernasal testosterone gel formulations for treating a female subject with anorgasmia and/or hypoactive sexual desire disorder.
1 . A testosterone gel formulation for nasal administration, said testosterone gel formulation comprising:
a. about 0.15% testosterone by weight of said gel formulation; and
b. a pharmaceutically acceptable vehicle.
2 . The testosterone gel formulation of claim 1 , wherein said gel formula further comprises a solvent, a wetting agent, and a viscosity increasing agent.
3 . The testosterone gel formulation of claim 2 , wherein said solvent is castor oil.
4 . The testosterone gel formulation of claim 2 , wherein said wetting agent is an oleoyl polyoxylglyceride.
5 . The testosterone gel formulation of claim 2 , wherein said viscosity increasing agent is colloidal silicon dioxide.
6 . The testosterone gel formulation of any one of claims 1 or 2 , wherein said gel formulation further comprises castor oil, oleoyl polyoxylglycerides and colloidal silicon dioxide.
7 . The testosterone gel formulation of any one of claims 1 - 6 , wherein said gel formulation is a bioequivalent formulation.
8 . The testosterone gel formulation of any one of claims 1 - 6 , wherein said gel formulation is a pharmaceutically equivalent formulation.
9 . The testosterone gel formulation of any one of claims 1 - 6 , wherein said gel formulation is a therapeutically equivalent formulation.
10 . A packaged pharmaceutical comprising:
(a) a testosterone gel formulation for nasal administration or a pharmaceutically acceptable salt or prodrug thereof, wherein said gel formulation comprises about 0.15% by weight; and
(b) associated instructions for using said testosterone gel formulation to treat anorgasmia.
11 . A packaged pharmaceutical comprising:
(a) a testosterone gel formulation for nasal administration or a pharmaceutically acceptable salt or prodrug thereof, wherein said gel formulation comprises about 0.15% by weight; and
(b) associated instructions for using said testosterone gel formulation to treat hypoactive sexual desire disorder (HSDD).
12 . The packaged pharmaceutical of claim 10 or 11 , wherein said testosterone is present as a pharmaceutical composition comprising a therapeutically effective amount of testosterone or a pharmaceutically acceptable salt or prodrug thereof and a pharmaceutically acceptable carrier.
13 . The packaged pharmaceutical of claim 10 or 11 , further comprising a step of identifying a subject in need of said pharmaceutical.
14 . A method of treating anorgasmia comprising administering intranasally to each nostril of a subject said gel formulation of any one of claims 1 - 9 to deliver a therapeutically effective amount of testosterone to effectively treat anorgasmia.
15 . A method of treating hypoactive sexual desire disorder (HSDD), comprising administering intranasally to each nostril of a subject said gel formulation of any one of claims 1 - 9 to deliver a therapeutically effective amount of testosterone to effectively treat HSDD.
16 . An intranasal method of treating a subject diagnosed with anorgasmia with a testosterone gel formulation for nasal administration comprising about 0.15% testosterone by weight of said gel formulation, comprising: applying the testosterone gel formulation into each nostril of said subject at least once a day to deliver an effective amount of testosterone to treat the anorgasmia.
17 . The method of claim 16 , wherein said subject receives said testosterone gel intranasally twice daily.
18 . An intranasal method of treating a subject diagnosed with HSDD with a testosterone gel formulation for nasal administration comprising about 0.15% testosterone by weight of said gel formulation, comprising: applying the testosterone gel formulation into each nostril of said subject at least once a day to deliver an effective amount of testosterone to treat the HSDD.
19 . The method of claim 18 , wherein said subject receives said testosterone gel intranasally twice daily.
20 . A testosterone gel formulation for nasal administration, said testosterone gel formulation comprising:
a. about 0.24% testosterone by weight of said gel formulation; and
b. a pharmaceutically acceptable vehicle.
21 . The testosterone gel formulation of claim 20 , wherein said gel formula further comprises a solvent, a wetting agent, and a viscosity increasing agent.
22 . The testosterone gel formulation of claim 21 , wherein said solvent is castor oil.
23 . The testosterone gel formulation of claim 22 , wherein said wetting agent is an oleoyl polyoxylglyceride.
24 . The testosterone gel formulation of claim 22 , wherein said viscosity increasing agent is colloidal silicon dioxide.
25 . The testosterone gel formulation of any one of claim 20 or 21 , wherein said gel formulation further comprises castor oil, oleoyl polyoxylglycerides and colloidal silicon dioxide.
26 . The testosterone gel formulation of any one of claims 20 - 25 , wherein said gel formulation is a bioequivalent formulation.
27 . The testosterone gel formulation of any one of claims 20 - 25 , wherein said gel formulation is a pharmaceutically equivalent formulation.
28 . The testosterone gel formulation of any one of claims 20 - 25 , wherein said gel formulation is a therapeutically equivalent formulation.
29 . A packaged pharmaceutical comprising:
(a) a testosterone gel formulation for nasal administration or a pharmaceutically acceptable salt or prodrug thereof, wherein said gel formulation comprises about 0.24% by weight; and
(b) associated instructions for using said testosterone gel formulation to treat anorgasmia.
30 . A packaged pharmaceutical comprising:
(a) a testosterone gel formulation for nasal administration or a pharmaceutically acceptable salt or prodrug thereof, wherein said gel formulation comprises about 0.24% by weight; and
(b) associated instructions for using said testosterone gel formulation to treat hypoactive sexual desire disorder (HSDD).
31 . The packaged pharmaceutical of claim 29 or 30 , wherein said testosterone is present as a pharmaceutical composition comprising a therapeutically effective amount of testosterone or a pharmaceutically acceptable salt or prodrug thereof and a pharmaceutically acceptable carrier.
32 . The packaged pharmaceutical of claim 29 or 30 , further comprising a step of identifying a subject in need of said pharmaceutical.
33 . A method of treating anorgasmia comprising administering intranasally to a subject said gel formulation of any one of claims 20 - 28 to deliver a therapeutically effective amount of testosterone to effectively treat HSDD.
34 . A method of treating hypoactive sexual desire disorder (HSDD), comprising administering intranasally to each nostril of a subject said gel formulation of any one of claims 20 - 28 to deliver a therapeutically effective amount of testosterone to effectively treat HSDD.
35 . An intranasal method of treating a subject diagnosed with anorgasmia with a testosterone gel formulation for nasal administration comprising about 0.24% testosterone by weight of said gel formulation, comprising: applying the testosterone gel formulation into each nostril of said subject at least once a day to deliver an effective amount of testosterone to treat the anorgasmia.
36 . The method of claim 35 , wherein said subject receives said testosterone gel intranasally twice daily.
37 . An intranasal method of treating a subject diagnosed with HSDD with a testosterone gel formulation for nasal administration comprising about 0.24% testosterone by weight of said gel formulation, comprising: applying the testosterone gel formulation into each nostril of said subject at least once a day to deliver an effective amount of testosterone to treat the HSDD.
38 . The method of claim 37 , wherein said subject receives said testosterone gel intranasally twice daily.